Friday, 13 August 2021 18:52

Anticoagulation news items. Weeks commencing 9th August 2021

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

The Lancet
Review of 95 cases of cerebral VTE after COVID vaccine found 70 classed as vaccine-induced immune thrombotic thrombocytopenia (VITT). Death or dependency was more common in VITT cases. Non-heparin anticoagulants & IV immunoglobulin reduced risk of death or dependency in VITT.


Edoxaban in Cardiovascular Disease Management: Review

British Journal of Clinical Pharmacology
This review provides a detailed outline of the growing indications, including thromboembolic and peripheral arterial disease, evidence for use in special populations, pharmacogenetics, and side effect profile of edoxaban.


Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial

Subgroup analysis (2185 of 6564) found rivaroxaban linked to lower incidence of composite endpoint of acute limb ischaemia, major vascular amputation,MI,CVA, or CVD vs placebo (18.4 vs 22.0% with cumulative incidence at 3 yrs of 19.7 & 23.9%,respectively;HR 0.81;95% CI 0.67-0.98).


Bleeding and thrombotic risk in pregnant women with Fontan physiology

Retrospective cohort study (n=84 undergoing 108 pregnancies) found current antithrombotic strategies appear effective at attenuating thrombotic risk (3 [2.8%] pregnancies complicated by thrombotic events) but with high (>30% bleeding risk, of which 13% life threatening).


Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

New England Journal of Medicine
Study (n=294, UK) reported overall mortality was 22% and was highest (73%) among patients with a low platelet count (<30,000/cubic millimetre) and intracranial haemorrhage. Treatment remains uncertain, but identification of prognostic markers may help guide effective management.


Clexane ® (enoxaparin sodium) device – Important Information regarding differences between PREVENTIS and ERIS needle guard safety systems

Sanofi UK
From August 2021, Clexane pre-filled syringes with both ERIS and PREVENTIS safety systems will be in the supply chain simultaneously. This healthcare professional communication highlights the differences in the needle guard safety systems between the two devices.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: